Frontier Medicines is a precision medicine company developing a platform aimed at generating therapies against disease-causing proteins previously considered undruggable. The company operates at the intersection of chemoproteomics, covalent drug discovery, and machine learning to identify novel binding sites and actionable leads across the proteome.
Its lead clinical program targets KRAS G12C, a mutation found most prevalently in non-small cell lung, colorectal, and pancreatic cancers. The program focuses on direct inhibition of both the activated and inactive forms of the protein. The company's proprietary Druggability Atlas platform is designed to identify thousands of druggable opportunities across the proteome.
Frontier Medicines is based in South San Francisco and Boston, operating within the precision medicine and oncology sectors.
